Arthritis Society of Canada Funds Medical Marijuana Research for Fibromyalgia Pain

Arthritis Society of Canada Funds Medical Marijuana Research for Fibromyalgia Pain
The Arthritis Society of Canada is awarding a three-year research grant to Dr. Mark Ware to study the use of medical marijuana (cannabis) for fibromyalgia pain. Ware is the director of clinical research at the Alan Edwards Pain Management Unit at McGill University in Montreal, Canada. He also serves as executive director of the nonprofit Canadian Consortium for the Investigation of Cannabinoids. Understanding the role that medical cannabis can play in mediating pain management is critical for patients and clinicians. Although many pain patients report that medical marijuana can ease their symptoms, there is not much scientific data to support these claims. And there are no large-scale clinical trials on the use of cannabinoids to treat fibromyalgia pain. The Arthritis Society hopes to help fill this gap. "These investments are about leading by example," Janet Yale, president and CEO of The Arthritis Society, said in a press release. "Patients and physicians both need to be able to make informed decisions about whether cannabis has a place in the individual's treatment plan." The pain that patients with fibromyalgia experience can be quite broad. It varies not only in intensity but also in location and frequency. These symptoms are often associated with broader ailments, ranging from sleep disorders to gastrointestinal problems. As a result, the pain can be debilitating to patients. "This disease has a tremendous impact on a person's life, but to date we haven't really had any good treatment options to offer," Ware said. "Opioids a
Subscribe or to access all post and page content.